These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32225075)

  • 21. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin.
    Baran A; Kiluk P; Świderska M; Maciaszek M; Myśliwiec H; Flisiak I
    Lipids; 2019 Aug; 54(8):445-452. PubMed ID: 31281982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Elevated level of serum PCSK9 in patients with systemic lupus erythematosus].
    Fang C; Luo T; Chen X; Lin L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):541-545. PubMed ID: 30236208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
    J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.
    Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Hirano T; Michishita I
    Lipids Health Dis; 2016 Sep; 15(1):165. PubMed ID: 27658826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population.
    Paquette M; Luna Saavedra YG; Chamberland A; Prat A; Christensen DL; Lajeunesse-Trempe F; Kaduka L; Seidah NG; Dufour R; Baass A
    Metab Syndr Relat Disord; 2017 Oct; 15(8):423-429. PubMed ID: 28749722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
    Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
    Chan DC; Hamilton SJ; Rye KA; Chew GT; Jenkins AJ; Lambert G; Watts GF
    Diabetes Obes Metab; 2010 Sep; 12(9):752-6. PubMed ID: 20649626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration.
    Miyazawa H; Honda T; Miyauchi S; Domon H; Okui T; Nakajima T; Tabeta K; Yamazaki K
    Clin Chim Acta; 2012 Jan; 413(1-2):154-9. PubMed ID: 22001517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.
    Wang S; Cheng ZY; Zhao ZN; Quan XQ; Wei Y; Xia DS; Li JQ; Hu JL
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1135-9. PubMed ID: 27049268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum Cholesteryl Ester Transfer Protein (CETP) and Sortilin (SORT) in Patients with Psoriasis with Relation to Systemic Treatment.
    Nowowiejska J; Baran A; Krahel JA; Kamiński TW; Maciaszek M; Flisiak I
    Metabolites; 2022 Apr; 12(4):. PubMed ID: 35448527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
    Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
    Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants.
    Araki S; Suga S; Miyake F; Ichikawa S; Kinjo T; Yamamoto Y; Kusuhara K
    Early Hum Dev; 2014 Oct; 90(10):607-11. PubMed ID: 25134067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
    Ferri N; Ruscica M
    Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.